Renal transporters in drug development

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 503-529

  Morrissey, Kari M ^a   Stocker, Sophie L ^a   Wittwer, Matthias B ^a   Xu, Lu ^a   Giacomini, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ABC transporters; drug metabolism; nephrotoxicity; pharmacokinetics; renal clearance; SLC transporters

Indexed keywords

ADEFOVIR; ADRENALIN; AMANTADINE; AMILORIDE; CARRIER PROTEIN; CEFALEXIN; CEPHALOSPORIN; CIDOFOVIR; CIMETIDINE; COLCHICINE; DEXAMETHASONE; DIMESNA; DOPAMINE; ETOPOSIDE; FAMOTIDINE; FUROSEMIDE; GANCICLOVIR; GLUTARIC ACID; LEVOFLOXACIN; MEMANTINE; METFORMIN; METHOTREXATE; OLMESARTAN; PENICILLIN DERIVATIVE; PRAVASTATIN; RANITIDINE; ROSUVASTATIN; TENOFOVIR; TRIMETHOPRIM; UNINDEXED DRUG;

ALTERNATIVE RNA SPLICING; DRUG CLEARANCE; DRUG TRANSPORT; DRUG UPTAKE; ETHNICITY; GLOMERULAR FILTRATION BARRIER; HUMAN; KIDNEY CLEARANCE; NEPHROTOXICITY; NONHUMAN; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; KIDNEY TUBULES; METABOLIC DETOXICATION, DRUG; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; XENOBIOTICS;

EID: 84872257350     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011112-140317     Document Type: Review

References (95)

1. Povey S, Lovering R, Bruford E, Wright M, Lush M,Wain H. 2001. The HUGO Gene Nomenclature Committee (HGNC). Hum. Genet. 109:678-80
2. Schlessinger A, Matsson P, Shima JE, Pieper U, Yee SW, et al. 2010. Comparison of human solute carriers. Protein Sci. 19:412-28
3. IMS Inst. Healthc. Inform. 2011. Top 200 drugs in the US market by dispensed prescriptions, 2010. Pharm. Times, April. http://www.pharmacytimes. com/media/pdf/26babf64401fed80734dbf8dce471e26.pdf
4. US Food Drug Admin. 2012. Guidance for industry: drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. US Food Drug Admin., Silver Spring, MD. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
5. RowlandM,TozerTN,eds. 2010. Clinical Pharmacokinetics and Pharmacodynamics: Concepts andApplications. Philadelphia: Wolters Kluwer Health/LippincottWilliam &Wilkins. 4th ed.
6. Hsyu PH, Gisclon LG, Hui AC, Giacomini KM. 1988. Interactions of organic anions with the organic cation transporter in renal BBMV. Am. J. Physiol. 254:F56-61
7. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, et al. 2002. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 300:918-24
8. Ahn SY, Eraly SA, Tsigelny I, Nigam SK. 2009. Interaction of organic cations with organic anion transporters. J. Biol. Chem. 284:31422-30
9. Brunton LL, Chabner BA, Knollman BC, eds. 2010. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill. 12th ed.
10. Moffat AC, Osselton MD,Widdop B, eds. 2004. Clarke's Analysis of Drugs and Poisons. London: Pharmaceutical Press. 3rd ed.
11. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. 1987. Reduction of metformin renal tubular secretion by cimetidine in man. Br. J. Clin. Pharmacol. 23:545-51
12. Gibaldi M, Schwartz MA. 1968. Apparent effect of probenecid on the distribution of penicillins in man. Clin. Pharmacol. Ther. 9:345-49
13. US Food Drug Admin. 1999. Highlights of Prescribing Information: VistideR-(cidofovir injection). US Food Drug Admin., Silver Spring, MD. http://www.accessdata.fda.gov/drugsatfda-docs/label/1999/020638s003lbl.pdf
14. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, et al. 1995. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39:1247-52
15. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. 1999. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. 56:570-80
16. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9:215-36
17. Leabman MK, Giacomini KM. 2003. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 13:581-84
18. Yin OQ, Tomlinson B, ChowMS. 2006. Variability in renal clearance of substrates for renal transporters in Chinese subjects. J. Clin. Pharmacol. 46:157-63
19. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, et al. 2011. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117:333-45
20. Shawahna R, Uchida Y, Decleves X, Ohtsuki S, Yousif S, et al. 2011. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 8:1332-41
21. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, et al. 2012. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 40:83-92
22. Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, et al. 2011. A common 5-UTR variant in MATE2-K is associated with poor response to metformin. Clin. Pharmacol. Ther. 90:674-84
23. Urban TJ, Brown C, Castro RA, Shah N, Mercer R, et al. 2008. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin. Pharmacol. Ther. 83:416-21
24. Chen Y, Li S, Brown C, Cheatham S, Castro RA, et al. 2009. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics 19:497-504
25. Urban TJ. 2010. Race, ethnicity, ancestry, and pharmacogenetics. Mt. Sinai J. Med. 77:133-39
26. Yee SW, Chen L, Giacomini KM. 2010. Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics 11:475-79
27. DeGorter MK, Xia CQ, Yang JJ, Kim RB. 2012. Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol. 52:249-73
28. Sun H, Frassetto L, Benet LZ. 2006. Effects of renal failure on drug transport and metabolism. Pharmacol. Ther. 109:1-11
29. Naud J, Nolin TD, Leblond FA, Pichette V. 2012. Current understanding of drug disposition in kidney disease. J. Clin. Pharmacol. 52:10S-22S
30. Zhang L, Xu N, Xiao S, Arya V, Zhao P, et al. 2012. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. J. Clin. Pharmacol. 52:79S-90S
31. Musso CG,Michelangelo H, Vilas M, Reynaldi J,Martinez B, et al. 2009. Creatinine reabsorption by the aged kidney. Int. Urol. Nephrol. 41:727-31
32. Coulthard MG, Hey EN, Ruddock V. 1985. Creatinine and urea clearances compared to inulin clearance in preterm and mature babies. Early Hum. Dev. 11:11-19
33. Gordjani N, Burghard R, Leititis JU, Brandis M. 1988. Serum creatinine and creatinine clearance in healthy neonates and prematures during the first 10 days of life. Eur. J. Pediatr. 148:143-45
34. Sonntag J, Prankel B, Waltz S. 1996. Serum creatinine concentration, urinary creatinine excretion and creatinine clearance during the first 9 weeks in preterm infants with a birth weight below 1500 g. Eur. J. Pediatr. 155:815-19
35. Aperia A, Broberger O, ElinderG,Herin P, Zetterstrom R. 1981. Postnatal development of renal function in pre-term and full-term infants. Acta Paediatr. Scand. 70:183-87
36. Mannan MA, Shahidulla M, Salam F, Alam MS, Hossain MA, Hossain M. 2012. Postnatal development of renal function in preterm and term neonates. Mymensingh Med. J. 21:103-8
37. Kearns GL. 2000. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J. Allergy Clin. Immunol. 106:S128-38
38. Lichtman SM, Skirvin JA, Vemulapalli S. 2003. Pharmacology of antineoplastic agents in older cancer patients. Crit. Rev. Oncol. Hematol. 46:101-14
39. Anderson GD, Lynn AM. 2009. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy 29:680-90
40. Trifiro G, Spina E. 2011. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr. Drug Metab. 12:611-20
41. Guignard JP, Torrado A, Da Cunha O, Gautier E. 1975. Glomerular filtration rate in the first three weeks of life. J. Pediatr. 87:268-72
42. Yaffe SJ. 1976. Developmental factors influencing interactions of drugs. Ann. N. Y. Acad. Sci. 281:90-97
43. Hook JB, HewittWR. 1977. Development of mechanisms for drug excretion. Am. J. Med. 62:497-506
44. Litovitz TL, Flagler SL, Manoguerra AS, Veltri JC, Wright L. 1989. Recurrent poisonings among paediatric poisoning victims. Med. Toxicol. Adverse Drug Exp. 4:381-86
45. Chen N, Aleksa K, Woodland C, Rieder M, Koren G. 2006. Ontogeny of drug elimination by the human kidney. Pediatr. Nephrol. 21:160-68
46. Inui KI, Masuda S, Saito H. 2000. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 58:944-58
47. van Kalken CK, Giaccone G, van der Valk P, Kuiper CM, Hadisaputro MM, et al. 1992. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am. J. Pathol. 141:1063-72
48. Tune BM. 1975. Relationship between the transport and toxicity of cephalosporins in the kidney. J. Infect. Dis. 132:189-94
49. Jacobs RF, Darville T, Parks JA, Enderlin G. 1992. Safety profile and efficacy of cefotaxime for the treatment of hospitalized children. Clin. Infect. Dis. 14:56-65
50. Lindheimer MD,Davison JM, Katz AI. 2001. The kidney and hypertension in pregnancy: twenty exciting years. Semin. Nephrol. 21:173-89
51. Jeyabalan A, Conrad KP. 2007. Renal function during normal pregnancy and preeclampsia. Front. Biosci. 12:2425-37
52. Koetje PM, Spaan JJ, Kooman JP, Spaanderman ME, Peeters LL. 2011. Pregnancy reduces the accuracy of the estimated glomerular filtration rate based on Cockroft-Gault and MDRD formulas. Reprod. Sci. 18:456-62
53. Quadri KH, Bernardini J, Greenberg A, Laifer S, Syed A, Holley JL. 1994. Assessment of renal function during pregnancy using a random urine protein to creatinine ratio and Cockcroft-Gault formula. Am. J. Kidney Dis. 24:416-20
54. Alper AB, Yi Y, Rahman M, Webber LS, Magee L, et al. 2011. Performance of estimated glomerular filtration rate prediction equations in preeclamptic patients. Am. J. Perinatol. 28:425-30
55. Alper AB, Yi Y, Webber LS, Pridjian G, Mumuney AA, et al. 2007. Estimation of glomerular filtration rate in preeclamptic patients. Am. J. Perinatol. 24:569-74
56. Schou M, Amdisen A, Steenstrup OR. 1973. Lithium and pregnancy: II. Hazards to women given lithium during pregnancy and delivery. Br. Med. J. 2:137-38
57. Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, et al. 2007. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin. Pharmacol. Ther. 81:547-56
58. Assael BM, Como ML, Miraglia M, Pardi G, Sereni F. 1979. Ampicillin kinetics in pregnancy. Br. J. Clin. Pharmacol. 8:286-88
59. Heikkila A, Erkkola R. 1991. Pharmacokinetics of piperacillin during pregnancy. J. Antimicrob. Chemother. 28:419-23
60. Wang H, Wu X, Hudkins K,Mikheev A, Zhang H, et al. 2006. Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am. J. Physiol. Endocrinol. Metab. 291:E1295-304
61. Zhang H,Wu X,Wang H,Mikheev AM,Mao Q, Unadkat JD. 2008. Effect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course. Mol. Pharmacol. 74:714-23
62. Eyal S, Easterling TR, Carr D, Umans JG, Miodovnik M, et al. 2010. Pharmacokinetics of metformin during pregnancy. Drug Metab. Dispos. 38:833-40
63. Hebert MF, Easterling TR, Kirby B, Carr DB, Buchanan ML, et al. 2008. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin. Pharmacol. Ther. 84:248-53
64. Anderson GD. 2005. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44:989-1008
65. Fesler P, Mimran A. 2011. Estimation of glomerular filtration rate: What are the pitfalls? Curr. Hypertens. Rep. 13:116-21
66. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. 2011. Performance of serum cystatin C versus serum creatinine as a marker of glomerular filtration rate as measured by inulin renal clearance. Clin. Exp. Nephrol. 15:868-76
67. Rahn KH, Heidenreich S, Bruckner D. 1999. How to assess glomerular function and damage in humans. J. Hypertens. 17:309-17
68. Schuetz EG, Furuya KN, Schuetz JD. 1995. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275:1011-18
69. Wolbold R, Klein K, Burk O, Nussler AK,Neuhaus P, et al. 2003. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-88
70. Wong LT, Sitar DS, Aoki FY. 1995. Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. Br. J. Clin. Pharmacol. 39:81-84
71. Godfrey C, Sweeney K, Miller K, Hamilton R, Kremer J. 1998. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br. J. Clin. Pharmacol. 46:369-76
72. Mattison D, Zajicek A. 2006. Gaps in knowledge in treating pregnant women. Gend. Med. 3:169-82
73. Uhl K, Parekh A, Kweder S. 2007. Females in clinical studies:Where are we going? Clin. Pharmacol. Ther. 81:600-2
74. Yang Y, Carlin AS, Faustino PJ, Motta MI, Hamad ML, et al. 2009. Participation of women in clinical trials for new drugs approved by the Food and Drug Administration in 2000-2002. J. Women's Health 18:303-10
75. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, et al. 2006. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J. Am. Soc. Nephrol. 17:2937-44
76. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, et al. 2007. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 53:766-72
77. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. 2009. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53:982-92
78. Hu OY, Ding PY, Huang CS, Hwang GM, Chu KM. 1997. Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. J. Clin. Pharmacol. 37:834-40
79. Zhou HH, Sheller JR, Nu H, Wood M, Wood AJ. 1993. Ethnic differences in response to morphine. Clin. Pharmacol. Ther. 54:507-13
80. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, et al. 2003. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302:2141-44
81. Mironov AA, Fickett JW, Gelfand MS. 1999. Frequent alternative splicing of human genes. Genome Res. 9:1288-93
82. Brett D, Hanke J, Lehmann G, Haase S, Delbruck S, et al. 2000. EST comparison indicates 38% of human mRNAs contain possible alternative splice forms. FEBS Lett. 474:83-86
83. KanZ,Rouchka EC, GishWR,States DJ. 2001. Gene structure prediction and alternative splicing analysis using genomically aligned ESTs. Genome Res. 11:889-900
84. Modrek B, Resch A, Grasso C, Lee C. 2001. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 29:2850-59
85. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, et al. 2005. Function of alternative splicing. Gene 344:1-20
86. Gamba G. 2001. Alternative splicing and diversity of renal transporters. Am. J. Physiol. Ren. Physiol. 281:F781-94
87. Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, et al. 2006. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17:2127-35
88. Hosoyamada M, Sekine T, Kanai Y, Endou H. 1999. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 276:F122-28
89. Bahn A, Prawitt D, Buttler D, Reid G, Enklaar T, et al. 2000. Genomic structure and in vivo expression of the human organic anion transporter 1 (hOAT1) gene. Biochem. Biophys. Res. Commun. 275:623-30
90. Robertson EE, Rankin GO. 2006. Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol. Ther. 109:399-412
91. Lamhonwah AM, Tein I. 1998. Carnitine uptake defect: frameshift mutations in the human plasmalemmal carnitine transporter gene. Biochem. Biophys. Res. Commun. 252:396-401
92. Wang Y, Ye J, Ganapathy V, Longo N. 1999. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc. Natl. Acad. Sci. USA 96:2356-60
93. Urakami Y, Akazawa M, SaitoH,Okuda M, Inui K. 2002. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol. 13:1703-10
94. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, et al. 2009. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther. 329:185-91
95. Morrissey KM, Wen CC, Johns SJ, Zhang L, Huang S-M, Giacomini KM. 2012. The UCSF-FDA TransPortal: a public drug transporter database. Clin. Pharmacol. Ther. 92:545-46